In this case, we report a patient with a treatment-resistant epilepsy <i>GABRB3</i> genetic variant phenotype who was admitted for sepsis and found to have significant thrombocytopenia with clinical manifestations of epistaxis and easy bruising, which was found to be due to VPA use rather than secondary to other clinical pathologies. This evidence concerns the gene GABRB3 and epilepsy.